Tempus AI (formerly Tempus Labs) is a U.S.-based precision medicine company founded in 2015 in Chicago by Eric Lefkofsky. It aims to revolutionize healthcare by combining molecular diagnostics, real-world clinical data, and artificial intelligence to guide personalized treatment decisions, particularly in oncology but also across areas like cardiology, neurology, psychiatry, and radiology.
đź’ˇ What They Do
-
Diagnostics: They offer genomic and molecular testing services (e.g. next‑generation sequencing assays) to profile tumors and individual patients.
-
Data Platform & AI: They maintain a rapidly growing, de-identified clinical database integrated with molecular data. Their suite of AI tools helps analyze and interpret complex datasets to inform diagnostics, treatment planning, trial matching, and outcomes prediction.
-
Life Sciences Services: Tempus supports pharmaceutical and biotech companies with analytics, digital biomarkers, and endpoints to accelerate clinical research and drug development.
🌍 Reach & Impact
-
Recognized as a leading provider in precision oncology, Tempus serves many U.S. oncologists and life-science partners.
-
They have strategic collaborations across the pharmaceutical and diagnostics ecosystems.
-
After going public (NASDAQ: TEM), they rebranded as “Tempus AI” to underscore their focus on data-driven, AI solutions.
